Cover Image
市場調查報告書

全球關節內粘稠補充療法市場考察,機會分析,市場佔有率,預測

Viscosupplementation Global Analysis & Market Insights, Opportunity, Analysis, Market Shares And Forecast 2016 - 2022

出版商 Occams Business Research & Consulting Pvt. Ltd. 商品編碼 358437
出版日期 內容資訊 英文 140 Pages
商品交期: 請詢問到貨日
價格
Back to Top
全球關節內粘稠補充療法市場考察,機會分析,市場佔有率,預測 Viscosupplementation Global Analysis & Market Insights, Opportunity, Analysis, Market Shares And Forecast 2016 - 2022
出版日期: 2016年05月04日 內容資訊: 英文 140 Pages
簡介

全球關節內粘稠補充療法市場,一般認為至2021年將達到17億5,600萬美元,預計2015年∼2021年以6%的年複合成長率成長。

本報告提供全球關節內粘稠補充療法市場相關調查分析,市場概要,市場決策要素,各部門分析,市場區隔,競爭情形,各地區分析,企業簡介等系統性資訊。

第1章 簡介

第2章 市場概要

  • 市場定義和範圍
  • 主要調查結果
  • 參數分析
  • 主要市場考察
  • 競爭情形
  • 五力分析模型
  • 主要的購買標準
  • 策略性建議
  • 策略性結論

第3章 市場決策要素

  • 推動市場要素
  • 阻礙市場要素
  • 市場機會

第4章 各部門分析

  • 親市場
  • 競爭市場
  • 替代市場

第5章 市場區隔

第6章 各地區分析

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 俄羅斯
  • 亞太地區
    • 中國
    • 印度
    • 韓國
  • 中東、非洲
  • 中南美

第7章 企業簡介

  • Ajinomoto
  • AB ENZYMES
  • BASF SE
  • AMANO ENZYME INC
  • THE DOW CHEMICAL COMPANY
  • ARCHER DANIELS MIDLAND COMPANY
  • NOVOZYMES A/S
  • CARGILL INCORPORATION
  • EVONIK INDUSTRIES AG
  • DU PONT DANISCO A/S
  • DSM
  • CHR
  • 扶桑化學工業
  • HOFFMANN-LA ROCHE
  • AMINO

圖表

目錄
Product Code: HPH-2340316

Viscosupplementation is the latest treatment which is being rapidly adapted these days for the treatment of osteoarthritis. It is a method of injecting hyaluronic acid in stiff joints specially knees. Due to the global adoption, the Viscosupplementation market is expected to hit $1756 million during 2015-2021 growing at an impressive CAGR of 6% during the forecast period. The main reason behind a solid growth of Viscosupplementation market on the global level is the rapid rise in the elderly population suffering from osteoarthritis. This elderly population is expected to increase in future due to advancement in the healthcare facilities which would ultimately require Disco supplementation for patients suffering from osteoarthritis during the forecast period.

Further, Intra-articular Viscosupplementation with hyaluronic acid (HA) is gaining a good acceptance as a therapeutic alternative to knee replacement surgery in OA in the past decade. North America is expected to be the largest market for Viscosupplementation during the forecast period in which the US being the major contributor to the global market for Viscosupplementation. On the flip side, APAC is seeing good growth in demand for Viscosupplementation fluids due to rising cases of osteoarthritis in countries such as India and China. However, the growing concern of physicians who updated American Academy of Orthopedic Surgeons (AAOS) and Osteoarthritis Research Society International (OARSI) treatment guidelines for knee OA will affect in rising insurance denials for Viscosupplementation. Further the price competition and product differentiation are some of the factors that can restrict the smooth growth of the market during the forecast period.

Table of Contents

1. INTRODUCTION

  • 1.1. EXECUTIVE SUMMARY
  • 1.2. ESTIMATION METHODOLOGY

2. MARKET OVERVIEW

  • 2.1. MARKET DEFINITION AND SCOPE
  • 2.2. KEY FINDINGS
  • 2.3. PARAMETRIC ANALYSIS
  • 2.4. KEY MARKET INSIGHTS
    • 2.4.1. TOP 3 EMERGING COUNTRIES
    • 2.4.2. TOP 3 REVENUE GENERATING SEGMENTS
    • 2.4.3. TOP GROWING MARK
    • 2.4.4. TOP 3 GEOGRAPHY
  • 2.5. COMPETITIVE LANDSCAPE
    • 2.5.1. MARKET SHARE ANALYSIS
    • 2.5.2. TOP WINNING STRATEGIES
    • 2.5.3. CASE STUDIES: TOP COMPETITIVE MOVES
  • 2.6. PORTER'S FIVE FORCE MODEL
    • 2.6.1. THREAT OF NEW ENTRANTS
    • 2.6.2. THREAT OF SUBSTITUTE PRODUCTS OR SERVICES
    • 2.6.3. BARGAINING POWER OF BUYER
    • 2.6.4. BARGAINING POWER OF SUPPLIER
    • 2.6.5. INTENSITY OF COMPETITIVE RIVALRY
  • 2.7. KEY BUYING CRITERIA
  • 2.8. STRATEGIC RECOMMENDATIONS
  • 2.9. STRATEGIC CONCLUSIONS

3. MARKET DETERMINANTS

  • 3.1. MARKET DRIVERS
    • 3.1.1. RISING PREVALENCE OF OA
    • 3.1.2. VISCOSUPPLEMENTATION DELAYS TOTAL KNEE REPLACEMENT
    • 3.1.3. SIDE EFFECTS OF NSAIDS, CORTICOSTEROIDS, AND NARCOTICS
    • 3.1.4. DIRECT-TO-CONSUMER MARKETING
  • 3.2. MARKET RESTRAINTS
    • 3.2.1. UNFAVOURABLE REIMBURSEMENT SCENARIO
    • 3.2.2. PRICING EROSION
    • 3.2.3. COST EFFECTIVE PHARMACOLOGICAL THERAPIES
    • 3.2.4. RISING POPULARITY OF PRP INJECTION TO IMPACT VISCOSUPPLEMENTATION
    • 3.2.5. COST-CONSCIOUS PATIENTS IN EMERGING COUNTRIES
  • 3.3. MARKET OPPORTUNITIES
    • 3.3.1. EXPANDING INDICATIONS
    • 3.3.2. NEW GENERATION HA DERIVATIVES
    • 3.3.3. INCREASED USE AFTER ARTHROSCOPIC SURGERIES
    • 3.3.4. SELF-PAY MARKET
    • 3.3.5. EMERGING COUNTRIES

4. SECTOR ANALYSIS

  • 4.1. PARENT MARKET
  • 4.2. COMPETITORS MARKET
  • 4.3. ALTERNATIVE MARKET

5. MARKET SEGMENTATION

6. GEOGRAPHIC ANALYSIS

  • 6.2. NORTH AMERICA
    • 6.2.1. NORTH AMERICA VISCOSUPPLEMENTATION MARKET BY APPLICATION, 2014-2021 ($BILLION)
    • 6.2.2. NORTH AMERICA VISCOSUPPLEMENTATION MARKET BY REGION, 2014-2021 ($BILLION)
      • 6.2.2.1. US VISCOSUPPLEMENTATION MARKET BY APPLICATION, 2014-2021 ($BILLION)
      • 6.2.2.2. CANADA VISCOSUPPLEMENTATION MARKET BY APPLICATION, 2014-2021 ($BILLION)
      • 6.2.2.3. MEXICO VISCOSUPPLEMENTATION MARKET BY APPLICATION, 2014-2021 ($BILLION)
  • 6.3 EUROPE
    • 6.3.1. EUROPE VISCOSUPPLEMENTATION MARKET BY APPLICATION, 2014-2021 ($BILLION)
    • 6.3.2. EUROPE VISCOSUPPLEMENTATION MARKET BY REGION, 2014-2021 ($BILLION)
      • 6.3.2.1. GERMANY VISCOSUPPLEMENTATION MARKET BY APPLICATION, 2014-2021 ($BILLION)
      • 6.3.3.2. UK VISCOSUPPLEMENTATION MARKET BY APPLICATION, 2014-2021 ($BILLION)
      • 6.3.3.3. RUSSIA VISCOSUPPLEMENTATION MARKET BY APPLICATION, 2014-2021 ($BILLION)
  • 6.4. ASIA PACIFIC
    • 6.4.1. ASIA PACIFIC VISCOSUPPLEMENTATION MARKET BY APPLICATION, 2014-2021 ($BILLION)
    • 6.4.2. ASIA PACIFIC VISCOSUPPLEMENTATION MARKET BY REGION, 2014-2021 ($BILLION)
      • 6.4.2.1. CHINA VISCOSUPPLEMENTATION MARKET BY APPLICATION, 2014-2021 ($BILLION)
      • 6.4.2.2. INDIA VISCOSUPPLEMENTATION MARKET BY APPLICATION, 2014-2021 ($BILLION)
      • 6.4.2.3. SOUTH KOREA VISCOSUPPLEMENTATION MARKET BY APPLICATION, 2014-2021 ($BILLION)
  • 6.5. MIDDLE EAST & AFRICA
    • 6.5.1. MIDDLE EAST & AFRICA VISCOSUPPLEMENTATION MARKET BY APPLICATION, 2014-2021 ($BILLION)
    • 6.5.2. MIDDLE EAST & AFRICA VISCOSUPPLEMENTATION MARKET BY REGION, 2014-2021 ($BILLION)
  • 6.6. CENTRAL & SOUTH AMERICA
    • 6.6.1. CENTRAL & SOUTH AMERICA VISCOSUPPLEMENTATION MARKET BY APPLICATION, 2014-2021 ($BILLION)
    • 6.6.2. CENTRAL & SOUTH AMERICA VISCOSUPPLEMENTATION MARKET BY REGION, 2014-2021 ($BILLION)
      • 6.6.2.1. BRAZIL VISCOSUPPLEMENTATION MARKET BY APPLICATION, 2014-2021 ($BILLION)

7 COMPANY PROFILES

  • 7.1. AJINOMOTO COMPANY INCORPORATION
  • 7.2. AB ENZYMES
  • 7.3. BASF SE
  • 7.4. AMANO ENZYME INC
  • 7.5. THE DOW CHEMICAL COMPANY
  • 7.6. ARCHER DANIELS MIDLAND COMPANY
  • 7.7. NOVOZYMES A/S
  • 7.8. CARGILL INCORPORATION.
  • 7.9. EVONIK INDUSTRIES AG
  • 7.10. DU PONT DANISCO A/S
  • 7.11. DSM
  • 7.12. CHR
  • 7.13. FUSO CHEMICAL
  • 7.14. HOFFMANN-LA ROCHE
  • 7.15. AMINO

TABLE LIST

  • TABLE 1 US PROCEDUREAL TRENDS FOR VISCOSUPPLEMENTATION, BY JOINT TYPE, 2014-2021
  • TABLE 2 US PROCEDUREAL TRENDS FOR VISCOSUPPLEMENTATION, BY TREATMENT REGIMEN, 2014-2021
  • TABLE 3 5EU PROCEDUREAL TRENDS FOR VISCOSUPPLEMENTATION, BY JOINT TYPE, 2014-2021
  • TABLE 4 EUROPE PROCEDURE TRENDS FOR VISCOSUPPLEMENTATION, BY TREATMENT REGIMEN, 2014-2021
  • TABLE 5 APAC PROCEDURE TRENDS FOR VISCOSUPPLEMENTATION, BY JOINT TYPE, 2014-2021
  • TABLE 6 APAC PROCEDURE TRENDS FOR VISCOSUPPLEMENTATION, BY TREATMENT REGIMEN, 2014-2021
  • TABLE 7 BRAZIL PROCEDURE TRENDS FOR VISCOSUPPLEMENTATION, BY JOINT TYPE, 2014-2021
  • TABLE 8 BRAZIL PROCEDURE TRENDS FOR VISCOSUPPLEMENTATION, BY TREATMENT REGIMEN, 2014-2021
  • TABLE 9 DIFFERENCES BETWEEN US FDA APPROVAL AND EU CE MARKING OF MEDICAL DEVICES
  • TABLE 10 US MEDICARE ASPS* FOR VISCOSUPPLEMENTATION PRODUCTS (2014-2015)
  • TABLE 11 PROBLEMS ASSOCIATED WITH KNEE REPLACEMENT
  • TABLE 12 SIDE-EFFECTS CAUSED BY NSAIDS
  • TABLE 13 SIDE EFFECTS OF CORTICOSTEROIDS
  • TABLE 14 SIDE EFFECTS OF NARCOTICS
  • TABLE 15 VISCOSUPPLEMENTATION DOSING
  • TABLE 16 MEDICAL NECESSITIES FOR THE PROCESS
  • TABLE 17 TOTAL HEALTH EXPENDITURE PER CAPITA INCOME IN $ IN 2015
  • TABLE 18 PRODUCT PROFILE (ADANT)
  • TABLE 19 PRODUCT PROFILE (ARTHRUM)
  • TABLE 20 ARTHRUM COMPOSITION AND RATIO IN CAPSULES
  • TABLE 21 PRODUCT PROFILE (CURAVISC)
  • TABLE 22 PRODUCT PROFILE (DUROLANE)
  • TABLE 23 PRODUCT PROFILE (EUFLEXXA)
  • TABLE 24 PRODUCT PROFILE (FERMATHRON)
  • TABLE 25 PRODUCT PROFILE (GEL-ONE)
  • TABLE 26 PRODUCT PROFILE (GO-ON)
  • TABLE 27 PRODUCT PROFILE (JONEXA)
  • TABLE 28 PRODUCT PROFILE (JONEXA)
  • TABLE 29 PRODUCT PROFILE (NEOVISC)
  • TABLE 30 PRODUCT PROFILE (ORTHOVISC AND MONOVISC)
  • TABLE 31 PRODUCT PROFILE (OSTENIL)
  • TABLE 32 PRODUCT PROFILE (RECOSYN)
  • TABLE 33 PRODUCT PROFILE (RENEHAVIS)
  • TABLE 34 PRODUCT PROFILE (SUPARTZ/ARTZ)
  • TABLE 35 PRODUCT PROFILE (SUPLASYN)
  • TABLE 36 PRODUCT PROFILE (SUVENYL)
  • TABLE 37 PRODUCT PROFILE (SYNOCROM)
  • TABLE 38 PRODUCT PROFILE (SYNOLIS V-A)
  • TABLE 39 PRODUCT PROFILE (SYNOVIAL)
  • TABLE 40 PRODUCT PROFILE (SYNVISC AND SYNVISC-ONE)
  • TABLE 41 EACH 1 ML OF GEL-SYN CONTAINS:
  • TABLE 42 SEIKAGAKU CORPORATION PRODUCTS PORTFOLIO
  • TABLE 43 SCOT ANALYSIS - SEIKAGAKU CORPORATION
  • TABLE 44 BIOVENTUS LLC PRODUCTS PORTFOLIO
  • TABLE 45 SCOT ANALYSIS - BIOVENTUS LLC
  • TABLE 46 DEPUY SYNTHES PRODUCTS PORTFOLIO
  • TABLE 47 SCOT ANALYSIS - DEPUY SYNTHES
  • TABLE 48 ZIMMER BIOMET INC PRODUCTS PORTFOLIO
  • TABLE 49 SCOT ANALYSIS - ZIMMER BIOMET INC
  • TABLE 50 SANOFI PRODUCTS PORTFOLIO
  • TABLE 51 SCOT ANALYSIS - SANOFI
  • TABLE 52 ANIKA THERAPEUTICS PRODUCTS PORTFOLIO
  • TABLE 53 SCOT ANALYSIS - ANIKA THERAPEUTICS
  • TABLE 54 CHUGAI PHARMACEUTICALS PRODUCTS PORTFOLIO
  • TABLE 55 SCOT ANALYSIS - CHUGAI PHARMACEUTICALS
  • TABLE 56 FERRING HOLDINGS PRODUCTS PORTFOLIO
  • TABLE 57 SCOT ANALYSIS - FERRING HOLDINGS
  • TABLE 58 FIDIA FARMACEUTICI S.P.A. PRODUCTS PORTFOLIO
  • TABLE 59 SCOT ANALYSIS - FIDIA FARMACEUTICI S.P.A.
  • TABLE 60 MEDA AB PRODUCTS PORTFOLIO
  • TABLE 61 SCOT ANALYSIS - MEDA AB
  • TABLE 62 GLOBAL VISCOSUPPLEMENTATION MARKET BY REGION, 2014-2021 ($ MILLION)
  • TABLE 63 GLOBAL VISCOSUPPLEMENTATION MARKET REVENUE ($ MILLION), BY SEGMENT, 2014-2021
  • TABLE 64 SINGLE INJECTION IN VISCOSUPPLEMENTATION COST AND DIFFERENT BRAND
  • TABLE 65 ONE-INJECTION MARKET, BY REGION 2014-2021($MILLION)
  • TABLE 66 THREE-INJECTION MARKET, BY REGION 2014-2021($ MILLION)
  • TABLE 67 MULTIPLE INJECTIONS IN VISCOSUPPLEMENTATION
  • TABLE 68 GLOBAL VISCOSUPPLEMENTATION MARKET BY GEOGRAPHY, 2014-2021 ($ MILLION)
  • TABLE 69 US VISCO SUPPLEMENTATION MARKET BY REVENUE ($ MILLION) 2014-2021
  • TABLE 70 FRANCE VISCO SUPPLEMENTATION MARKET BY REVENUE ($ MILLION) 2014-2021
  • TABLE 71 GERMANY VISCO SUPPLEMENTATION MARKET BY REVENUE ($ MILLION), 2014-2021
  • TABLE 72 SPAIN VISCOSUPPLEMENTATION MARKET BY REVENUE ($ MILLION), 2014-2021
  • TABLE 73 UK VISCO SUPPLEMENTATION MARKET BY REVENUE($ MILLION), 2014-2021
  • TABLE 74 JAPAN VISCOSUPPLEMENTATION MARKET BY REVENUE ($ MILLION), 2014-2021
  • TABLE 75 BRAZIL VISCOSUPPLEMENTATION MARKET BY REVENUE($ MILLION), 2014-2021
  • TABLE 76 CHINA VISCO SUPPLEMENTATION MARKET BY REVENUE($ MILLION), 2014-2021
  • TABLE 77 INDIA VISCOSUPPLEMENTATION MARKET BY REVENUE ($ MILLION), 2014-2021

FIGURES LIST

  • FIGURE 1 GLOBAL VISCOSUPPLEMETATION PROCEDURAL TRENDS BY TREATMENT REGIME (%) 2014 AND 2021
  • FIGURE 2 GLOBAL VISCOSUPPLEMENTATION PROCEDURAL TRENDS BY JOINT TYPE (%) 2014 AND 2021
  • FIGURE 3 US ADOPTION TREND FOR VISCOSUPPLEMENTATION, BY TREATMENT REGIMEN, 2014
  • FIGURE 4 US PROCEDURE TRENDS FOR VISCOSUPPLEMENTATION, BY TREATMENT REGIMEN, 2012-2021
  • FIGURE 5 5EU PROCEDURE TRENDS FOR VISCOSUPPLEMENTATION, BY JOINT TYPE, 2014
  • FIGURE 6 5EU ADOPTION TRENDS FOR VISCOSUPPLEMENTATION, BY TREATMENT REGIMEN, 2014
  • FIGURE 7 5EU PROCEDURE TRENDS FOR VISCOSUPPLEMENTATION, BY TREATMENT REGIMEN, 2012-2021
  • FIGURE 8 APAC PROCEDURE TRENDS FOR VISCOSUPPLEMENTATION, BY TREATMENT REGIMEN, 2012-2021
  • FIGURE 9 APAC PROCEDURE TRENDS FOR VISCOSUPPLEMENTATION, BY JOINT TYPE, 2014
  • FIGURE 10 APAC ADOPTION TREND FOR VISCOSUPPLEMENTATION, BY TREATMENT REGIMEN, 2014
  • FIGURE 11 BRAZIL PROCEDURE TRENDS FOR VISCOSUPPLEMENTATION, BY JOINT TYPE, 2014
  • FIGURE 12 BRAZIL ADOPTION TREND FOR VISCOSUPPLEMENTATION, BY TREATMENT REGIMEN, 2014
  • FIGURE 13 BRAZIL PROCEDURE TRENDS FOR VISCOSUPPLEMENTATION, BY TREATMENT REGIMEN, 2012-2021
  • FIGURE 14 GLOBAL VISCOSUPPLEMENTATION MARKET ACCESS BY REGION 2014-2021 (%)
  • FIGURE 15 PAYER MIX FOR VISCOSUPPLEMENTATION IN THE US, 2014
  • FIGURE 16 PAYER MIX FOR VISCOSUPPLEMENTATION IN FRANCE, 2014
  • FIGURE 17 PAYER MIX FOR VISCOSUPPLEMENTATION IN THE UK, 2014
  • FIGURE 18 PAYER MIX FOR VISCOSUPPLEMENTATION IN SPAIN, 2014
  • FIGURE 19 PAYER MIX FOR VISCOSUPPLEMENTATION IN CHINA, 2014
  • FIGURE 20 LIFE TIME RISK OF SYMPTOMATIC OSTEOARTHRITIS
  • FIGURE 21 GLOBAL PREVALENCE ARTHRITIS BY AGE (%) IN 2014
  • FIGURE 22 COMMONLY USED NSAIDS, CORTICOSTEROIDS, NARCOTICS
  • FIGURE 23 ADVANTAGES OF DIRECT-TO-CONSUMER MARKETING
  • FIGURE 24 THE COMMON PHARMACOLOGICAL THERAPIES AVAILABLE FOR OA
  • FIGURE 25 AVERAGE PER CAPITA INCOME IN DEVELOPED AND DEVELOPING COUNTRIES IN 2014
  • FIGURE 26 HYALURONIC ACID DERIVATIVES
  • FIGURE 27 STEPS INCLUDED IN SELF PAY MARKET
  • FIGURE 28 GROWTH OF VISCOSUPPLEMENTATION MARKET IN APAC REGION IN US $ MILLION 2015-2020
  • FIGURE 29 FEATURES OF NEOVISC
  • FIGURE 30 US VISCOSUPPLEMENTATION MARKET BY JOINT TYPE IN 2014(%)
  • FIGURE 31 FRANCE, GERMANY, ITALY SPAIN AND UK VISCOSUPPLEMENTATION MARKET GROWTH 2014-2021($ MILLION)
  • FIGURE 32 INDIA, CHINA AND JAPAN VISCOSUPPLEMENTATION MARKET GROWTH 2014-2021($ MILLION)
  • FIGURE 33 GLOBAL VISCOSUPPLEMENTATION ONE-INJECTION MARKET REVENUE ($M) 2012-2021
  • FIGURE 34 GLOBAL VISCOSUPPLEMENTATION THREE-INJECTION MARKET REVENUE ($M), BY REGION, 2012-2021
  • FIGURE 35 FIVE-INJECTION MARKET, BY COUNTRY 2012-2021($ MILLION)
  • FIGURE 36 GLOBAL VISCOSUPPLEMENTATION FIVE-INJECTION MARKET REVENUE ($ MILLION), BY REGION, 2012-2021
  • FIGURE 37 GROWTH IN NUMBER OF PATIENTS SUFFERING FROM OSTEOARTHRITIS BY GENDER (2005-2030)
  • FIGURE 38 FRANCE VISCOSUPPLEMENTATION MARKET REVENUE $ MILLION 2014-2021
  • FIGURE 39 CAUSES OF OSTEOARTHRITIS
  • FIGURE 40 GERMANY VISCOSUPPLEMENTATION MARKET REVENUE $MILLION 2014-2021
  • FIGURE 41 HIP REPLACEMENT SURGERY PER 100 000 POPULATION 2013
  • FIGURE 42 ITALY VISCOSUPPLEMENTATION MARKET REVENUE $ MILLION 2014-2021
  • FIGURE 43 REDUCTION IN PAIN AND STIFFNESS AFTER MONO INJECTION
  • FIGURE 44 SPAIN VISCOSUPPLEMENTATION MARKET REVENUE $ MILLION 2014-2021
  • FIGURE 45 NUMBER OF OSTEOARTHRITIS PATIENTS IN SPAIN BY AGE
  • FIGURE 46 KNEE OPERATIONS FOR OBESE PEOPLE IN 2012-13 BY GENDER
  • FIGURE 47 UK VISCOSUPPLEMENTATION MARKET REVENUE $ MILLION 2014-2021
  • FIGURE 48 JAPAN VISCOSUPPLEMENTATION MARKET REVENUE $ MILLION 2014-2021
  • FIGURE 49 PREVALENCE OF KNEE OSTEOARTHRITIS IN JAPAN BY GENDER IN 2014
  • FIGURE 50 BRAZIL VISCOSUPPLEMENTATION MARKET REVENUE $ MILLION 2014-2021
  • FIGURE 51 HEALTH EXPENDITURE AS PERCENTAGE OF GDP IN 2013
  • FIGURE 52 INDIA VISCOSUPPLEMENTATION MARKET REVENUE $ MILLION 2014-2021
Back to Top